Literature DB >> 11408392

Captopril suppression versus salt loading in confirming primary aldosteronism.

M Agharazii1, P Douville, J H Grose, M Lebel.   

Abstract

This prospective study was designed to compare the captopril suppression test with the salt-loading approach to confirm the diagnosis of primary aldosteronism. A total of 49 patients were referred with a presumed diagnosis of primary aldosteronism. The captopril test was performed in the morning with patients in the seated position after overnight fasting. Blood samples for plasma aldosterone were obtained before captopril administration (25 mg PO) and again 2 hours later. Patients were then subjected to a high salt diet (300 mmol sodium per day for 3 days). On the third day, urinary sodium (24 hours) was measured, and plasma aldosterone levels were measured at 8:00 AM (recumbent) and at noon (standing). Of the 49 patients, 44 had nonsuppressible aldosterone concentrations with all the clinical characteristics of primary aldosteronism: 22 patients had surgically confirmed unique adenoma, and 22 patients had presumed bilateral hyperplasia. There was a significant correlation between plasma aldosterone values of salt-loaded patients (mean of 8:00 AM and noon results) and the values 2 hours after captopril administration (r=0.8, P<0.01). Plasma aldosterone cumulative distribution curves in primary aldosteronism patients (adenoma and hyperplasia) were not significantly different between the 2 suppression tests. Our results showed that the captopril suppression test is as effective as sodium loading in confirming the diagnosis of primary aldosteronism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408392     DOI: 10.1161/01.hyp.37.6.1440

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

Review 1.  Diagnosis and surgical management for primary hyperaldosteronism.

Authors:  Ravi Munver; Jennifer Yates
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

2.  Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.

Authors:  G Bernini; A Bacca; V Carli; D Carrara; G Materazzi; P Berti; P Miccoli; R Pisano; V Tantardini; M Bernini; S Taddei
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 3.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

Review 4.  Functional tests for primary aldosteronism: value of captopril suppression.

Authors:  Marie-Claude Racine; Pierre Douville; Marcel Lebel
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 5.  Diagnosis and treatment of primary aldosteronism.

Authors:  Gian Paolo D Rossi
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

6.  Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.

Authors:  Alexander A Leung; Christopher J Symonds; Gregory L Hundemer; Paul E Ronksley; Diane L Lorenzetti; Janice L Pasieka; Adrian Harvey; Gregory A Kline
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

Review 7.  Prediction of successful outcome in patients with primary aldosteronism.

Authors:  Tracy-Ann Moo; Rasa Zarnegar; Quan-Yang Duh
Journal:  Curr Treat Options Oncol       Date:  2007-08

8.  Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism.

Authors:  François Corbin; Pierre Douville; Marcel Lebel
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-28

Review 9.  Hypertensive hypokalemic disorders.

Authors:  Kyu Bok Choi
Journal:  Electrolyte Blood Press       Date:  2007-06-30

10.  Diagnostic Role of Captopril Challenge Test in Korean Subjects with High Aldosterone-to-Renin Ratios.

Authors:  Jung Hee Kim; Kyeong Seon Park; A Ram Hong; Chan Soo Shin; Seong Yeon Kim; Sang Wan Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2016-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.